



focus27


Operation roadmap and update on financing: setting the foundations for future profitable growth 26 June 2024

pen p ssibilities

Certain information contained in this presentation is forward looking and not historical data. These forward-looking statements are based on opinions, projections and current assumptions including, but not limited to, assumptions concerning the Group's current and future strategy, financial and non-financial future results and the environment in which the Group operates, as well as events, operations, future services or product development and potential. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Forward looking statements and information do not constitute guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a large number of which are difficult to predict and generally outside the control of the Group, which could cause actual results, performances or achievements, or the results of the sector or other events, to differ materially from those described or suggested by these forward-looking statements. These risks and uncertainties include those that are indicated and detailed in Chapter 3 "Risk factors" of the Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 5, 2024. These forward-looking statements are given only as of the date of this presentation and the Group expressly declines any obligation or commitment to publish updates or corrections of the forward-looking statements include in this presentation in order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-looking statements are based.


Our strengths A unique API and CDMO offer

euroapi




Our strengths

EULOAH











Streamlined value-added portfolio, focused on highly differentiated profitable products Focused CDMO offer leveraging our recognized capabilities and technology platforms Rationalized industrial footprint prioritizing highreturn CAPEX Organizational transformation and more efficient ways of working

Revised commercial contractual terms with Sanofi

euroapi










Customers	Large established Biotech	Targeted prospection towards late-stage drugs and high-value projects driven by innovative complex chemistry
	Big Pharma	RSM & API re-shoring trends
		Need of marketed products (dual-sourcing)
Technology Platforms	One-stop-shop in Large Molecules	End-to-end offer in Oligonucleotides with BIANOGmp
		Innovative linkers development to offer conjugated complex molecules
		Complex Chemistry capabilities leveraged in development of next generation lipids and alternative processes on Peptide production
	Biofermentation and HP APIs	From R&D to large volume production in fermentation for small complex molecules
		Development of new HP APIs, including linkers payloads for XDC and new Prostaglandins

Objective: more than 1/3 of Group net sales by 2027


Rationalized industrial footprint Divesting and rightsizing





Rationalized industrial footprint Focusing and investing for growth

euroapi



Organizational transformation





Commercial

Redesign the Commercial teams to increase synergies, and efficiencies



Procurement

Accelerate direct procurement transformation Deploy on a new indirect procurement strategy



R&D


Focus on support to Commercial, in particular the CDMO business Strengthened technology platforms



Supply Chain

Strengthen End-to-End processes to improve the supply chain efficiency, increase capacity, drive lead-time and inventory reductions cc. 550* total headcounts reduction throughout the plan EUROAPI in 2027






A value-added API and CDMO offering

A streamlined industrial footprint


A more efficient organization

FOCUS-27 Net Sales breakdown

ΕυΓΟΑΡΙ




Acceleration of the CDMO business




FOCUS-27 increased profitability 75 to 80 M€ run-rate incremental EBITDA targeted by 2027*











*On any interest payment date, and subject to certain conditions, EUROAPI may decide to defer the interest payment related to this loan. This non-dilutive hybrid instrument will be classified as Equity in the consolidated financial statements.

euroapi

Underlying assumptions

- Downsizing of two large CMO contracts
- Strong decrease in sales to Sanofi
- Phasing impact in the CDMO business
- Impact of the suspension of APIs production in Brindisi
- A material impact of the company's transformation and early restructuring costs, including industrial under-activity resulting from the execution of the FOCUS 27 project
- Improvement in Working Capital, driven by a significant reduction in inventories, mainly in the second half

Between 8% and 11% decrease in Net Sales on a comparable basis. The secondhalf performance should exceed that of the first half due to phasing impact



Between 4% and 7% Core EBITDA margin

EUROAPI in 2027

A refocused company... more independent, more agile, more efficient, more innovative...

...reinvented to deliver long-term profitable growth to meet the needs of customers and patients worldwide in a more sustainable way





focus27

Operation roadmap and update on financing: setting the foundations for future profitable growth

pen p ssibilities